-
Patent Agency Ranking
公开(公告)号：US12195535B2
公开(公告)日：2025-01-14
申请号：US18162991
申请日：2023-02-01
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20240092907A1
公开(公告)日：2024-03-21
申请号：US18162991
申请日：2023-02-01
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
CPC classification number: C07K16/2812 , C07K2317/34 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US11795231B2
公开(公告)日：2023-10-24
申请号：US17670223
申请日：2022-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11603406B2
公开(公告)日：2023-03-14
申请号：US16493712
申请日：2018-03-13
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Andy X. Deng , Lin Hui Su , Ginger Rakestraw
IPC: C07K16/28
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20220073617A1
公开(公告)日：2022-03-10
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
-
-
-
Search Results
15
records
(took 0.017 seconds)
